In our study, anti-IL-33 antibody treatment reduced dysplasia, supporting the hypothesis that the presence of IL-33 in the tumour microenvironment is correlated with faster and more aggressive tumour development in some tumour models [45]. This evidence concerns the gene IL33 and neoplasm.